Nouscom

Executive Summary

Nouscom is a private, next-generation immunotherapy company based in Basel, Italy, founded in 2015. It specializes in engineered viral vectored vaccines for cancer treatment, developing both off-the-shelf and personalized neoantigen vaccines designed to induce robust anti-tumor T cell responses with favorable safety profiles. The company's proprietary platform leverages viral vector technology to deliver broad and potent immunogenicity. While Nouscom has not yet reported clinical data in public channels, its approach addresses key challenges in cancer immunotherapy, including tumor heterogeneity and immune evasion. The company is likely advancing its lead candidate NOUS-209, a personalized neoantigen vaccine, through early-stage clinical trials. With a strong scientific foundation and a differentiated technology, Nouscom is positioned to address significant unmet needs in oncology. Upcoming catalysts include clinical data readouts and potential partnership opportunities, which could drive valuation growth. However, as a private company, visibility into its progress is limited, and execution risks remain typical for early-stage biotech firms.

Upcoming Catalysts (preview)

• Q4 2026Phase 1/2 interim data for NOUS-209 in solid tumors65% success
• Q1 2027Initiation of Phase 2 trial for lead program75% success
• Q2 2027Potential strategic partnership or licensing deal40% success